Treatment of Ventilator-Associated Pneumonia

  • Richard G. Wunderink
Part of the Perspectives on Critical Care Infectious Diseases book series (CCID, volume 4)


Nearly two decades have past since the beginning of research on the diagnosis of ventilator-associated pneumonia (VAP). Despite significant increases in our understanding of the pathogenesis of VAP and the operating characteristics of various diagnostic methods, the primary goal of this research into diagnosis - improved treatment and prevention strategies - remains in its infancy. Rather than the well-designed, critically reviewed studies now being performed in VAP diagnosis (1,2), the majority of data regarding treatment of VAP continues to come from pharmaceutical industry sponsored trials, designed only to show equivalence to already marketed drugs.


Respir Crit Nosocomial Pneumonia Quantitative Culture Inappropriate Therapy Protected Specimen Brush 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al: Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: A pilot study. Am.1 Respir Crit Care Med 1998; 157: 371–376.CrossRefGoogle Scholar
  2. 2.
    Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 2000; 132: 621–630.PubMedGoogle Scholar
  3. 3.
    Wunderink RG: Mortality and the diagnosis of ventilator-associated pneumonia: A new direction. Am J Respir Crit Care Med 1998; 157: 349–350.PubMedCrossRefGoogle Scholar
  4. 4.
    Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22: 387–394.PubMedCrossRefGoogle Scholar
  5. 5.
    Celis R, Torres A, Gatell JM, Almela M, Rodriquez-Roisin R, Agusti-Vidal A: Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93: 318–324.PubMedCrossRefGoogle Scholar
  6. 6.
    Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1997; (In Press)Google Scholar
  7. 7.
    Luna CM, Vujacich P, Niederman MS, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676–685.PubMedCrossRefGoogle Scholar
  8. 8.
    Rello J, Gallego M, Mariscal D, Sonora R, Valles J: The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196–200.PubMedCrossRefGoogle Scholar
  9. 9.
    Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–474.PubMedCrossRefGoogle Scholar
  10. 10.
    American Thoracic Society: Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A Consensus Statement. Am J Respir Crit Care Med 1995; 153: 1711–1725.Google Scholar
  11. 11.
    Rello J, Sa-Borges M, Correa H, Leal S-R, Baraibar J: Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608–613.PubMedCrossRefGoogle Scholar
  12. 12.
    Trouillet J-L, Chastre J, Vuagnat A, et al: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531–539.PubMedCrossRefGoogle Scholar
  13. 13.
    Brewer S, Wunderink R, Jones C, Leeper K: Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109: 1019–1029.CrossRefGoogle Scholar
  14. 14.
    Wunderink R, Leeper K, Jennings SG, Jones C: Effect of ATS-recommended antibiotic therapy on mortality of Pseudomonas ventilator-associated pneumonia (PsVAP). Am l Respir Crit Care Med 1998; 157: A294(Abstract)Google Scholar
  15. 15.
    Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280(14): 1233–1237.(Abstract)PubMedCrossRefGoogle Scholar
  16. 16.
    Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353–358.PubMedGoogle Scholar
  17. 17.
    Carmeli Y, Trouillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicr Ag Chemother 1999; 43: 1379–1382.Google Scholar
  18. 18.
    Trouillet JL, Vuagnat A, Kassis N, et al: Predictors-of ticarcillin resistance in ventilator-associated pneumonia (VAP) caused by P. aeruginosa. Am J Respir Crit Care Med 2000; 1611: A294(Abstract)Google Scholar
  19. 19.
    Baker AM, Meredith JW, Haponik EF: Pneumonia in intubated trauma patients: Microbiology and outcomes. Am.l Respir Crit Care Med 1996; 153: 343–349.CrossRefGoogle Scholar
  20. 20.
    Bonten MJM, Bergmans DCJJ, Stobberingh EE, et al: Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156: 1820–1824.PubMedCrossRefGoogle Scholar
  21. 21.
    Bonten MJM, Froon AHM, Gaillard CA, et al: The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 1105–1113.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker AM, Bowton DL, Haponick EF: Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantative bronchoscopic cultures. Chest 1995; 107: 85–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Cobben NAM, Jacobs JA, van Dieijen-Visser MP, Mulder PGH, Wouters EFM, Drent M: Diagnostic value of BAL fluid cellular profile and enzymes in infectious pulmonary disorders. Eur Respir J 1999; 14: 496–502.PubMedCrossRefGoogle Scholar
  24. 24.
    Salata RA, Lederman MM, Shlaes DM, et al: Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am Rev Respir Dis 1987; 135: 426–432.PubMedGoogle Scholar
  25. 25.
    Meduri GU, Mauldin GL, Wunderink RG, et al: Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 1994; 106:221–225.PubMedCrossRefGoogle Scholar
  26. 26.
    Rouby JJ, Laurent P, Gosnach M, et al: Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med 1994; 150: 776–783.PubMedCrossRefGoogle Scholar
  27. 27.
    Meehan TP, Fine MJ, Krumholz HM, et al: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–2084.PubMedCrossRefGoogle Scholar
  28. 28.
    Wunderink RG: Pharmacoeconomics of pneumonia. Am J Surg 2000; 179 (Suppl 2A): 51S–57S.Google Scholar
  29. 29.
    Croce MA, Fabian TC, Shaw B, et al: Analysis of charges associated with diagnosis of nosocomial pneumonia: can routine bronchoscopy be justified? J of Trauma 1994; 37: 721–727.CrossRefGoogle Scholar
  30. 30.
    Fagon J-Y, Chastre J, Domart Y, Trouillet.J-L, Gibert C: Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23: 538–542.PubMedCrossRefGoogle Scholar
  31. 31.
    Kollef MH, Silver P, Murphy DM, Trovillion E: The effect of late-onset ventilator-associated pneumonia determining patient mortality. Chest 1995; 108: 1655–1662.PubMedCrossRefGoogle Scholar
  32. 32.
    Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: 1230–1235.PubMedCrossRefGoogle Scholar
  33. 33.
    Fagon JY, Chastre J, Domart Y, et al: Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139: 877–884.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodriguez de Castro F, Sole Violan J, Lafarga Capuz B, Caminero Luna J, Gonzalez Rodriguez B, Manzano Alonso JL: Reliability of the bronchoscopic protected specimen brush in the diagnosis of pneumonia in mechanically ventilated patients. Crit Care Med 1991; 19: 171–175.PubMedCrossRefGoogle Scholar
  35. 35.
    Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother 1994; 38: 547–557.PubMedCrossRefGoogle Scholar
  36. 36.
    Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C: Treatment of ventilator-associated pneumonia with piperacillin-tazobactam amikacin versus cetazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346–354.PubMedCrossRefGoogle Scholar
  37. 37.
    Schentag JJ, Birmingham MC, Paladino JA, et al: In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect 1997; 12: 278–293.PubMedGoogle Scholar
  38. 38.
    The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–1698.CrossRefGoogle Scholar
  39. 39.
    A’Court CH, Garrard CS, Crook D, et al: Microbiological lung surveillance in mechanically ventilated patients, using non-directed bronchial lavage and quantitative culture. Quart J Med 1993; 86: 635–648.PubMedCrossRefGoogle Scholar
  40. 40.
    Montravers P, Fagon JY, Chastre J, et al: Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Souweine B, Veber B, Bedos JP, et al: Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage and nosocomial pneumonia: impact of previous antimicrobial treatment. Crit Care Med 1998; 26(2): 236–244.PubMedCrossRefGoogle Scholar
  42. 42.
    Dunn M, Wunderink R: Ventilator-associated pneumonia caused by Pseudomonas infection. Clin Chest Med 1995; 16: 95–109.PubMedGoogle Scholar
  43. 43.
    Rello J, Ausina V, Ricart M, et al: Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20: 193–198.PubMedCrossRefGoogle Scholar
  44. 44.
    Trouillet N, Samore MH, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094–1098.CrossRefGoogle Scholar
  45. 45.
    Sanders CC, Sanders WE: Type I -lactamases of gram-negative bacteria: interactions with -lactam antibiotics. J Infect Dis 1986; 154: 792–800.PubMedCrossRefGoogle Scholar
  46. 46.
    Hancock REW: Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(suppl 1): S93–S99PubMedCrossRefGoogle Scholar
  47. 47.
    Silver DR, Cohen IL, Weinberg PF: Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. Chest 1992; 101: 194–198.PubMedCrossRefGoogle Scholar
  48. 48.
    Cometta A, Baumgartner JD, Lew D, et al: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial Agents and Chemotherapy 1994; 38: 1309–1313.PubMedCrossRefGoogle Scholar
  49. 49.
    Brown RB, Kruse JA, Counts GW, et al: Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990; 34: 269–272.PubMedCrossRefGoogle Scholar
  50. 50.
    Rello J, Quintana E, Ausina V, Puzo C, Net A, Prats G: Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142: 1320–1324.PubMedCrossRefGoogle Scholar
  51. 51.
    Leeper KV, Jennings SG, Jones CB, Wunderink RG: Outcome of ventilator-associated pneumonia due to methicillin-resistant staphylococcus aureus. Chest 2000; 138S(Abstract)Google Scholar
  52. 52.
    Rouby JJ, De Lassale EM, Poete P, et al: Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 148: 1059–1066.CrossRefGoogle Scholar
  53. 53.
    Fagon J-Y, Patrick H, Haas DW, et al: treatment of gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753–762.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Richard G. Wunderink
    • 1
  1. 1.Research Department, Methodist Le Bonheur Healthcare FoundationUniversity of TennesseeMemphisUSA

Personalised recommendations